Medpace - Therapeutically Focused Clinical Development White Papers

Outsourcing Best Practices Strategic vs full service CROs - which is better? As with most questions in the clinical trial world, the easy and often accurate answer is “well, it depends”.
View white paper
Heart Hope Dr Thomas Todaro, Executive Medical Director of Medpace, talks to Future Pharmaceuticals about the global perspectives in Acute Coronary Syndrome (ACS) trial conduct and recruitment.
View white paper
Interview with Dr David Orloff Close Concerns recently had the distinct honor of discussing the recent FDA cardiovascular risk assessment guidelines for diabetes drugs with Dr. David Orloff, the former director of the division of metabolism and endocrinology products at FDA, and currently executive director of regulatory affairs at Medpace, Inc.
View white paper
Emerging Markets: Navigating the Path to Conduct Successful Clinical Trials in China As industry pressure to conduct successful global clinical trials on time and on budget continue, tapping emerging global markets will be crucial to deliver sustained growth to the pharmaceutical industry.
View white paper
Emerging Markets: Climate Change in Latin America Makes for Successful Clinical Trials The change in local regulatory guidelines ensuring faster project start-up, the ability to run trials six months out of phase for seasonal disease states, and the availability of highly motivated patients for clinical trials has the clinical development climate in Latin America heating up.
View white paper